UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation

UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation

Brief description of study

This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is sometimes used to treat certain kidney cancers.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    renal cell carcinoma
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 829195

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center